Pe cy7 anti mouse cd62l

Manufactured by BioLegend

Sourced in United States

PE/Cy7 anti-mouse CD62L is a fluorescently labeled antibody that binds to the CD62L (L-selectin) protein expressed on the surface of mouse cells. CD62L is a cell adhesion molecule involved in the homing of lymphocytes to peripheral lymph nodes.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

CD62L (93 citations) Anti-CD62L (35 citations) CD62L-PE/Cy7 (22 citations) CD62L-PE (16 citations) PE-anti-CD62L (15 citations) PE anti-mouse CD62L (6 citations) PE-Cy7-anti-CD62L (3 citations) Anti-mouse CD62L (3 citations) PE-Cy7-conjugated anti-mouse CD62L ( (2 citations)

6 protocols using pe cy7 anti mouse cd62l

Murine Splenocyte Phenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Preparation of splenocytes has been described (25 (link)). The following Abs were produced in the laboratory or purchased as indicated: anti-mouse CD11c PE/Cy7 (N418; Biolegend); anti-mouse TCRβ PerCP-Cy5.5 (H57–597; BioLegend); anti-mouse CD19 BUV395 (1D3; Becton Dickinson), anti-mouse CD19 AL488 (1D3.2); anti-mouse CD4 BV605 (RM4; Becton Dickinson), anti-mouse CD4 PE (GK1.5 Biolegend); anti-mouse CD62L PE/Cy7 (MEL-14; Biolegend); anti-mouse CD44 BV605 (1M7; Becton Dickinson), anti-mouse CD44 APC/Cy7 (IM7; Biolegend); anti-mouse I-A/I-E APC/Cy7 (M5/114.15.2; BioLegend); anti-mouse CD138 BV605 (281–2; Becton Dickinson), anti-mouse CD138 PE (281–2; Biolegend); anti-mouse CD8 PacBlue (TIB-105); anti-mouse CD38 AL680 (90), anti-mouse CD38 PacBlue (90); PNA AL488; anti-mouse kappa PacBlue (187.1); anti-mouse CD11b PE (M1/70; Becton Dickinson); anti-mouse CD35 AL647 (8C12); anti-mouse CD23 PE/Cy7 (B3B4; Biolegend); anti-mouse IgM AL647 (B7–6); anti-mouse IgG2a PE (Goat polyclonal; Southern Biotech). Flow cytometry data were collected on a BD LSR II or BD LSRFortessa and analyzed using FlowJo software (TreeStar).

Marinov A.D., Wang H., Bastacky S.I., van Puijenbroek E., Schindler T., Speziale D., Perro M., Klein C., Nickerson K.M, & Shlomchik M.J. (2021). The Type II anti-CD20 Antibody Obinutuzumab (GA101) is More Effective than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis & rheumatology (Hoboken, N.J.), 73(5), 826-836.

+ Open protocol

+ Expand

Lymphocyte Profiling in Vaccinated Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lymph nodes and spleens were harvested from vaccinated mice. These organs were then processed into a single cell suspension after being passed through a 40 μM strainer, lysed with ammonium-chloride-potassium (ACK) solution, and washed in Hank’s balanced salt solution (HBSS) containing 3% FBS before staining and fixation in 1% paraformaldehyde. Immune cell populations were identified by flow cytometry using an LSRII (BD Biosciences, San Jose, CA) and analyzed by FlowJo software (Tree Star, Ashland, OR). Lymph nodes or splenocytes were stained with anti-mouse CD3-FITC and anti-mouse CD44-APC purchased from eBioscience (San Diego, CA). Additionally, cells were stained for anti-mouse CD4-APC-Cy7, anti-mouse CD62L PeCy7, anti-mouse CD8-Pacific Blue, anti-mouse CD95-PE, anti-mouse CD19-PECy7, and anti-mouse GL-7 Pacific Blue (Biolegend, San Diego, CA).

Junkins R.D., Gallovic M.D., Johnson B.M., Collier M.A., Watkins-Schulz R., Cheng N., David C.N., McGee C.E., Sempowski G.D., Shterev I., McKinnon K., Bachelder E.M., Ainslie K.M, & Ting J.P. (2017). A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. Journal of controlled release : official journal of the Controlled Release Society, 270, 1-13.

+ Open protocol

+ Expand

Comprehensive Immune Profiling of Murine Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Carprofen (Rimadyl^® Injectable, 50 mg/mL) was purchased from Patterson Companies (Saint Paul, MN, USA). Pacific Blue™ anti-mouse CD3, FITC anti-mouse CD4, PerCP anti-mouse CD8a, PE anti-mouse/human CD11b, APC/Cy7 anti-mouse Ly-6G/Ly-6C (Gr-1), PE/Cy7 anti-mouse CD62L, APC anti-mouse/human CD44, APC anti-mouse CD25, Biolegend PE anti-mouse/rat/human FOXP3, PerCP anti-mouse CD11c, PE/Cy7 anti-mouse CD86, FITC anti-mouse I-A/I-E, and APC anti-mouse CD40 were purchased from Biolegend (San Diego, CA, USA). Mouse tumor dissociation kit (No. 130-096-730) was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

Guo S., Burcus N.I., Hornef J., Jing Y., Jiang C., Heller R, & Beebe S.J. (2018). Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile. Cancers, 10(7), 217.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Analysis of T Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Splenocytes were either stimulated with survivin or MUC1 protein for 12 h. Following incubation, the cells were stained with the following surface antibodies: APC anti-mouse CD8a (Biolegend), PE-Cy7 anti-mouse CD4 (Biolegend). Cells were then permeabilized and washed with the Cytofix/Cytoperm kit (BD Biosciences) according to manufacturer’s instructions. Intracellular Ki67 were subsequently stained with PE anti-mouse Ki67 (Biolegend). For central memory T cells (TCM) and effector memory T (TEM) cells, in addition to APC anti-mouse CD8a (Biolegend), PE anti-mouse CD44 (Biolegend) and PE-Cy7 anti-mouse CD62L (Biolegend) were used for cell surface staining. After staining, cells were washed, fixed, and analyzed using flow cytometry.

Guo Q., Wang L., Xu P., Geng F., Guo J., Dong L., Bao X., Zhou Y., Feng M., Wu J., Wu H., Yu B., Zhang H., Yu X, & Kong W. (2020). Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. Oncoimmunology, 9(1), 1841392.

+ Open protocol

+ Expand

Tumor-Induced Immune Responses in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

After challenging mice with 4T1 tumours for seven days, the inguinal lymph nodes and spleens were isolated and dissociated into single cells by mashing through cell strainers (70 μm). The inguinal lymph node and spleen cell suspensions were stained with APC anti-mouse CD3 (Biolegend), PE anti-mouse CD8a (Biolegend), PE/Cy7 anti-mouse CD62L (Biolegend), FITC anti-mouse/human CD44 (Biolegend), APC anti-mouse CD11c, FITC anti-mouse CD80, PE anti-mouse CD86 and APC anti-mouse CD3, and PE anti-mouse CD8a. The percentages of CD3+CD8+CD44+CD62− cells, CD11c+CD80+CD86+ cells, and CD3+CD8+ cells corresponding to effector memory T cells, DCs, and CD8+ T cells, were analysed by flow cytometry.

Xu X., Mao H., Wu Y., Liu S., Liu J., Li Q., Yang M., Zhu J., Zou S, & Du F. (2022). Fabrication of methylene blue-loaded ovalbumin/polypyrrole nanoparticles for enhanced phototherapy-triggered antitumour immune activation. Journal of Nanobiotechnology, 20, 297.

+ Open protocol

+ Expand

Characterization of Tumor-Infiltrating Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Seven days after challenging mice with 4T1 tumor, the inguinal lymph nodes and spleen were isolated and dissociated into single cells by mashing through cell strainers (70 μm). The cell suspension of inguinal lymph nodes was stained with APC anti-mouse CD3 (BioLegend), PE anti-mouse CD8a (BioLegend), PE/Cy7 anti-mouse CD62L (BioLegend), FITC anti-mouse/ human CD44 (BioLegend) and APC anti-mouse CD11c, FITC anti-mouse CD80, PE anti-mouse CD86 and APC anti-mouse CD3, PE anti-mouse CD8a, respectively. The cell suspension of spleen was stained with APC anti-mouse CD3 (BioLegend), PE anti-mouse CD8a (BioLegend). The percentage of CD3⁺CD8⁺CD44^highCD62^low cells, CD11c⁺CD80⁺CD86⁺ cells, and CD3⁺CD8⁺ corresponding to effector memory T cells, DC cells, CD8⁺ T cells was analyzed, respectively.

Zhang L., Zhang J., Xu L., Zhuang Z., Liu J., Liu S., Wu Y., Gong A., Zhang M, & Du F. (2021). NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses. Journal of Nanobiotechnology, 19, 142.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!